Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Real-World Treatment Patterns And Adverse Events In Metastatic Renal Cell Carcinoma From A Large Us Claims Database, Sumata Pal, Jun Gong, Shivani K. Mhatre, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen, Daniel George
Real-World Treatment Patterns And Adverse Events In Metastatic Renal Cell Carcinoma From A Large Us Claims Database, Sumata Pal, Jun Gong, Shivani K. Mhatre, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen, Daniel George
Faculty & Staff Scholarship
Background: Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) treatments for metastatic renal cell carcinoma (mRCC). Despite treatment availability, the 5-year survival rate in patients diagnosed at the metastatic stage is only ≈ 10%. To gain contemporary insights into RCC treatment trends that may inform clinical, scientific and payer considerations, treatment patterns and adverse events (AEs) associated with 1 L therapy were examined in a retrospective, longitudinal, population-based, observational study of patients with mRCC. Methods: US administrative claims data (Truven Health MarketScan Commercial Databases) were used to …